Filing Flows › Pacific Biosciences of California (PACB) › Q3 2026 › vs Q2 2026
Pacific Biosciences of California (PACB) Q3 2026 vs Q2 2026 (quarter over quarter)
Pacific Biosciences of California's revenue rose $1.6M (+4%) from $39.0M in Q2 2026 to $40.6M in Q3 2026.
Pacific Biosciences of California, Q3 2026: revenue $40.6M (+6% year over year), operating margin -91.2%, net loss $37.8M, operating cash flow −$37.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $40.6M | $39.0M | $1.6M | +4% |
| Net loss | $37.8M | $44.7M | −$6.9M | -15% |
| Costs & expenses | $78.4M | $83.7M | −$5.3M | -6% |
| Operating costs | $77.6M | $83.6M | −$6.1M | -7% |
| Interest & other, net | $575K | $73K | $502K | +688% |
| Income tax | $269K | $58K | $211K | +364% |
| Cost of revenue | $27.1M | $26.4M | $725K | +3% |
| Research & development | $20.2M | $23.0M | −$2.8M | -12% |
| SG&A | $29.4M | $33.4M | −$4.0M | -12% |
| Other operating costs | $833K | $833K | $0 | 0% |
| Operating cash sources | $48.6M | $47.2M | $1.4M | +3% |
| Depreciation | $2.5M | $2.3M | $140K | +6% |
| Share-based compensation | $8.5M | $9.3M | −$724K | -8% |
| Cash used in operations | $37.6M | $35.6M | $2.0M | +6% |
| Net loss absorbed | $37.8M | $44.7M | −$6.9M | -15% |
| Working capital & other | $10.8M | $2.4M | $8.3M | +343% |
Questions
How much did Pacific Biosciences of California's revenue grow quarter over quarter in Q3 2026?
Pacific Biosciences of California's revenue rose $1.6M (+4%) from $39.0M in Q2 2026 to $40.6M in Q3 2026.